DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM, today announced the signing of a 3 year master supply agreement with Eisai, based in Woodcliff Lake, NJ, USA, for the production of sterile products.
The agreement covers the production of eribulin mesylate as well as other developmental drugs.
DSM will be a supplier for eribulin mesylate to the US market. Commercial production is anticipated to start in early 2013. L
No financial details were disclosed.
This interview covers key results of the study ‘Success Factor Supply Chain Management and Logistics in the Chemical Industry 2024’ by Solventure, Aimms and Miebach.
Novo Nordisk recently announced changes to its executive leadership and Board of Directors.
The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.
Jens Birgersson becomes new Brenntag CEO
Honeywell will acquire Johnson Matthey's Catalyst Technologies business segment for €2.15 billion in an all-cash transaction.
